bluuebunny/crossref_metadata_2025 huggingface dataset:
Suppl. Figures 1-10 from Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status
Authors: Cea Michele , Cagnetta Antonia , Acharya Chirag , Acharya Prakrati , Tai Yu-Tzu , Yang Cao , Lovera Davide , Soncini Debora , Miglino Maurizio , Fraternali-Orcioni Giulio , Mastracci Luca , Nencioni Alessio , Montecucco Fabrizio , Monacelli Fiammetta , Ballestrero Alberto , Hideshima Teru , Chauhan Dharminder , Gobbi Marco , Lemoli Roberto M. , Munshi Nikhil , Treon Steven P. , Anderson Kenneth C.
Published: April 2023

Suppl. Fig.1. Nampt staining on normal Lymph Nodes; Suppl. Fig. 2. Nampt over-expression in BCMW.1 cells. Suppl. Fig. 3. Dose-response effect curves of FK866; Suppl. Fig. 4. Expression levels of Nampt in WM cells after BTK inhibition (GSE65816); Suppl. Fig. 5. MYD88 L265P and MYD88 WT expressing cells treated with FK866, ibrutinib, or both. Suppl. Fig. 6. MYD88 L265P (BCMW.1 and MWCL-1) and MYD88 WT ( MEC.1 and RL) expressing cells were treated with an inhibitor of Nampt (FK866), BTK (ibrutinib), or both. Suppl. Fig. 7. Effects of co-treatment on primary tumor cells. Suppl. Fig. 8. Densitometric analysis of WB represented in Figure 3B. Suppl. Fig. 9. Rescue experiments with exogenous NAD. Suppl. Fig. 10. Effects of co-treatments on animals body weight.
supplementary methods from Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer
Authors: Prieur Alexandre , Cappellini Monica , Habif Guillaume , Lefranc Marie-Paule , Mazard Thibault , Morency Eric , Pascussi Jean-Marc , Flacelière Maud , Cahuzac Nathalie , Vire Bérengère , Dubuc Benjamin , Durochat Amandine , Liaud Pierre , Ollier Jérémy , Pfeiffer Caroline , Poupeau Sophie , Saywell Véronique , Planque Chris , Assenat Eric , Bibeau Frédéric , Bourgaux Jean-François , Pujol Pascal , Sézeur Alain , Ychou Marc , Joubert Dominique
Published: April 2023

Contain all the supplementary methods linked to this paper
Supplementary Information from Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry
Authors: Trinh Anne , Trumpi Kari , De Sousa E Melo Felipe , Wang Xin , de Jong Joan H. , Fessler Evelyn , Kuppen Peter J.K. , Reimers Marlies S. , Swets Marloes , Koopman Miriam , Nagtegaal Iris D. , Jansen Marnix , Hooijer Gerrit K.J. , Offerhaus George J.A. , Kranenburg Onno , Punt Cornelis J. , Medema Jan Paul , Markowetz Florian , Vermeulen Louis
Published: April 2023

Contains code to reproduce the image analysis pipeline and the results in the study
supplementary figures 1 to 13 and supplementary tables 1 to 4 from Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer
Authors: Prieur Alexandre , Cappellini Monica , Habif Guillaume , Lefranc Marie-Paule , Mazard Thibault , Morency Eric , Pascussi Jean-Marc , Flacelière Maud , Cahuzac Nathalie , Vire Bérengère , Dubuc Benjamin , Durochat Amandine , Liaud Pierre , Ollier Jérémy , Pfeiffer Caroline , Poupeau Sophie , Saywell Véronique , Planque Chris , Assenat Eric , Bibeau Frédéric , Bourgaux Jean-François , Pujol Pascal , Sézeur Alain , Ychou Marc , Joubert Dominique
Published: April 2023

Contain all the supplemetary data linked to this paper
Supplemental methods and tables from Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry
Authors: Trinh Anne , Trumpi Kari , De Sousa E Melo Felipe , Wang Xin , de Jong Joan H. , Fessler Evelyn , Kuppen Peter J.K. , Reimers Marlies S. , Swets Marloes , Koopman Miriam , Nagtegaal Iris D. , Jansen Marnix , Hooijer Gerrit K.J. , Offerhaus George J.A. , Kranenburg Onno , Punt Cornelis J. , Medema Jan Paul , Markowetz Florian , Vermeulen Louis
Published: April 2023

Contains supplemental methods and supplementary figure legends. Also contains supplemental tables 1, 2 Table S1. Description of features used in the quantitative classifier Table S2. Multivariate survival analysis of the CAIRO and CAIRO2 cohorts with respect to treatment arm
Figure S5 from Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry
Authors: Trinh Anne , Trumpi Kari , De Sousa E Melo Felipe , Wang Xin , de Jong Joan H. , Fessler Evelyn , Kuppen Peter J.K. , Reimers Marlies S. , Swets Marloes , Koopman Miriam , Nagtegaal Iris D. , Jansen Marnix , Hooijer Gerrit K.J. , Offerhaus George J.A. , Kranenburg Onno , Punt Cornelis J. , Medema Jan Paul , Markowetz Florian , Vermeulen Louis
Published: April 2023

Fig. S5. Comparison of CMS-classification to the serrated adenoma pathway
Supplementary Figure and Table Legends from Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer
Authors: Liu Hong , Xu Yiyang , Xiang Jingyi , Long Li , Green Shon , Yang Zhiyuan , Zimdahl Bryan , Lu Jingwei , Cheng Neal , Horan Lucas H. , Liu Bin , Yan Su , Wang Pei , Diaz Juan , Jin Lu , Nakano Yoko , Morales Javier F. , Zhang Pengbo , Liu Lian-xing , Staley Binnaz K. , Priceman Saul J. , Brown Christine E. , Forman Stephen J. , Chan Vivien W. , Liu Cheng
Published: April 2023

Figure Legends for Sup. Figures 1-9 and Sup. Table 1
Supplementary Figure S1 from Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research
Authors: Land Stephanie R. , Toll Benjamin A. , Moinpour Carol M. , Mitchell Sandra A. , Ostroff Jamie S. , Hatsukami Dorothy K. , Duffy Sonia A. , Gritz Ellen R. , Rigotti Nancy A. , Brandon Thomas H. , Prindiville Sheila A. , Sarna Linda P. , Schnoll Robert A. , Herbst Roy S. , Cinciripini Paul M. , Leischow Scott J. , Dresler Carolyn M. , Fiore Michael C. , Warren Graham W.
Published: April 2023

This file contains the NCI-AACR tobacco use questionnaire and notes about its use.
Supplementary Data from Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research
Authors: Land Stephanie R. , Toll Benjamin A. , Moinpour Carol M. , Mitchell Sandra A. , Ostroff Jamie S. , Hatsukami Dorothy K. , Duffy Sonia A. , Gritz Ellen R. , Rigotti Nancy A. , Brandon Thomas H. , Prindiville Sheila A. , Sarna Linda P. , Schnoll Robert A. , Herbst Roy S. , Cinciripini Paul M. , Leischow Scott J. , Dresler Carolyn M. , Fiore Michael C. , Warren Graham W.
Published: April 2023

This file contains detailed information about the methodology.
Supplementary Data from Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
Authors: Siravegna Giulia , Sartore-Bianchi Andrea , Nagy Rebecca J. , Raghav Kanwal , Odegaard Justin I. , Lanman Richard B. , Trusolino Livio , Marsoni Silvia , Siena Salvatore , Bardelli Alberto
Published: April 2023

Correlation between pCN and tumor fraction in plasma where z=((2*(1-x))+(y*x)), and x is set from 0 to 100% as tumor fraction. Centiles of ERBB2 pCN in the Guardant Health database were as follows: copy number <2.4 (<50th percentile), >2.4 but < 4 (50th-90th percentile), and >4.0 ({greater than or equal to}90th percentile).
Figure A3 from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
Authors: Marachelian Araz , Villablanca Judith G. , Liu Cathy W. , Liu Betty , Goodarzian Fariba , Lai Hollie A. , Shimada Hiroyuki , Tran Hung C. , Parra Jaime A. , Gallego Richard , Bedrossian Nora , Young Sabrina , Czarnecki Scarlett , Kennedy Rebekah , Weiss Brian D. , Goldsmith Kelly , Granger Meaghan , Matthay Katherine K. , Groshen Susan , Asgharzadeh Shahab , Sposto Richard , Seeger Robert C.
Published: April 2023

Comparison of 1 year EFS in two groups defined by a range of Ã¢Ë†â€ CT cut points (left column) and corresponding ROC analysis of the ability of Ã¢Ë†â€ CT values above the cutpoint to predict 1 year EFS (right column), for assays based on different combinations of genes. NB5 assay (A, B), Phox2B/TH/DDC (C, D), Phox2B/TH (E, F), Phox2B/TH/Dcx (G, H), Th/Dcx (I, J). These analyses show that the NB5 assay is at least as or more predictive then the other gene combinations.
Supplementary Figure 5 from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI
Authors: Panek Rafal , Welsh Liam , Baker Lauren C.J. , Schmidt Maria A. , Wong Kee H. , Riddell Angela M. , Koh Dow-Mu , Dunlop Alex , Mcquaid Dualta , d'Arcy James A. , Bhide Shreerang A. , Harrington Kevin J. , Nutting Christopher M. , Hopkinson Georgina , Richardson Cheryl , Box Carol , Eccles Suzanne A. , Leach Martin O. , Robinson Simon P. , Newbold Kate L.
Published: April 2023

Examples of R2* time series (left column, R2* range 40 s-1) and corresponding power frequency spectra (R2* power range displayed: 0 - 30) for voxels within human HNSCC classified as significantly fluctuating (tumor - top two rows) and without significant fluctuations (tumor - middle two rows, adjacent muscle - bottom row).
Figure A1 from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
Authors: Marachelian Araz , Villablanca Judith G. , Liu Cathy W. , Liu Betty , Goodarzian Fariba , Lai Hollie A. , Shimada Hiroyuki , Tran Hung C. , Parra Jaime A. , Gallego Richard , Bedrossian Nora , Young Sabrina , Czarnecki Scarlett , Kennedy Rebekah , Weiss Brian D. , Goldsmith Kelly , Granger Meaghan , Matthay Katherine K. , Groshen Susan , Asgharzadeh Shahab , Sposto Richard , Seeger Robert C.
Published: April 2023

Correlation of morphologically-defined NB cells in BM and MIBG Curie score. Analysis of BM biopsies and MIBG scans were performed concurrently on 173 patients.
Table S1 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma
Authors: Wildes Tyler J. , Grippin Adam , Dyson Kyle A. , Wummer Brandon M. , Damiani David J. , Abraham Rebecca S. , Flores Catherine T. , Mitchell Duane A.
Published: April 2023

FACS Antibodies
Figure S6, S7, and S8 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma
Authors: Wildes Tyler J. , Grippin Adam , Dyson Kyle A. , Wummer Brandon M. , Damiani David J. , Abraham Rebecca S. , Flores Catherine T. , Mitchell Duane A.
Published: April 2023

T cell recognition of cognate antigen drives release of soluble factors including IFN-g and GM-CSF. T cell-released IFN-g and GM-CSF contribute to HSPC differentiation. Supernatant transfer with cytokine knockout T cells differentiates the roles of IFN-g and GM-CSF in HSPC differentiation and proliferation.
Figure S2 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma
Authors: Wildes Tyler J. , Grippin Adam , Dyson Kyle A. , Wummer Brandon M. , Damiani David J. , Abraham Rebecca S. , Flores Catherine T. , Mitchell Duane A.
Published: April 2023

IFN-g is upregulated in the brain tumor microenvironment during T cell immunotherapy and drives HSPC differentiation into CD11c+MHCII+ DCs.
Figure S1 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma
Authors: Wildes Tyler J. , Grippin Adam , Dyson Kyle A. , Wummer Brandon M. , Damiani David J. , Abraham Rebecca S. , Flores Catherine T. , Mitchell Duane A.
Published: April 2023

Intravenously administered HSPCs durably engraft in gliomas, supplant host immunity, and differentiate into antigen-presenting cells.
Supplemental Figure S9 from ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet–associated Colon Cancer
Authors: Mustafi Reba , Dougherty Urszula , Mustafi Devkumar , Ayaloglu-Butun Fatma , Fletcher Michelle , Adhikari Sarbani , Sadiq Farhana , Meckel Katherine , Haider Haider I. , Khalil Abdurahman , Pekow Joel , Konda Vani , Joseph Loren , Hart John , Fichera Alessandro , Li Yan Chun , Bissonnette Marc
Published: April 2023

Left panel ADAM17 WB of colonocytes and stromal cells. Vimentin and CK20 indicate stromal cell and colonocyte purity. Right panel: densitometry. Values means {plus minus} SD n=4 tumors and adjacent mucosal samples.
Figure S6 from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
Authors: Caumanns Joseph J. , Berns Katrien , Wisman G. Bea A. , Fehrmann Rudolf S.N. , Tomar Tushar , Klip Harry , Meersma Gert J. , Hijmans E. Marielle , Gennissen Annemiek M.C. , Duiker Evelien W. , Weening Desiree , Itamochi Hiroaki , Kluin Roelof J.C. , Reyners Anna K.L. , Birrer Michael J. , Salvesen Helga B. , Vergote Ignace , van Nieuwenhuysen Els , Brenton James , Braicu E. Ioana , Kupryjanczyk Jolanta , Spiewankiewicz Beata , Mittempergher Lorenza , Bernards René , van der Zee Ate G.J. , de Jong Steven
Published: April 2023

Supplementary Figure 6 | mTORC1, mTORC1/2 and PI3K-mTORC1/2 inhibitor sensitivities. (A) IC50 of the mTORC1 inhibitor temsirolimus from COSMICs drug screening database in all cancer cell lines vs. ovarian cancer cell lines, horizontal lines indicate geometric mean. (B) MTT assay curves from AZD8055 (left) or everolimus (right) treatment on the aforementioned cell line panel. (C) Expression of p-AKT308, p-AKT473 and p-S6 after 24 (up) and 72h (down) exposure to 100 nM everolimus, AZD8055 or MLN0128 in the OCCC cell lines KOC7C or JHOC5 determined by Western blot. ÃŽÂ²-Actin was used as loading control. Results are representative from n=2 experiments. (D) Expression of p-AKT308, p-AKT473, p-S6 and (cleaved) PARP after 48h exposure to increasing concentrations of everolimus, AZD8055 and dactolisib in the OCCC cell lines KOC7C (up) and JHOC5 (down) determined by Western blot. ÃŽÂ²-Actin was used as loading control. Results are representative from n=2 experiments. (E) Everolimus, AZD8055, GDC0941 and selumetinib IC50 determined for 14 OCCC cell lines (ES2, KOC7C, SMOV2, JHOC5, RMG1, OVMANA, HAC2, OV207, OVTOKO, TOV21G, OVAS, OVCA429, TUOC1 and RMG2) and dactolisib IC50 determined for 7 OCCC cell lines (ES2, KOC7C, SMOV2, JHOC5, RMG1, OVMANA and HAC2) by MTT assay. Selumetinib IC50 of KOC7C was not reached at maximum used concentration of 25 uM. Horizontal lines indicate geometric mean. Data is derived from n{greater than or equal to}2 experiments. (F) Long-term proliferation assay after exposure to increasing concentrations of AZD8055 and dactolisib. Results are representative from n=3 experiments.
Figure S1 from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
Authors: Caumanns Joseph J. , Berns Katrien , Wisman G. Bea A. , Fehrmann Rudolf S.N. , Tomar Tushar , Klip Harry , Meersma Gert J. , Hijmans E. Marielle , Gennissen Annemiek M.C. , Duiker Evelien W. , Weening Desiree , Itamochi Hiroaki , Kluin Roelof J.C. , Reyners Anna K.L. , Birrer Michael J. , Salvesen Helga B. , Vergote Ignace , van Nieuwenhuysen Els , Brenton James , Braicu E. Ioana , Kupryjanczyk Jolanta , Spiewankiewicz Beata , Mittempergher Lorenza , Bernards René , van der Zee Ate G.J. , de Jong Steven
Published: April 2023

Supplementary Figure 1 | Kinome sequencing variant filtering. Pipeline for filtering of kinome sequencing variants.
Supplementary Table S5 from Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment
Authors: Martinez-Garcia Elena , Lesur Antoine , Devis Laura , Cabrera Silvia , Matias-Guiu Xavier , Hirschfeld Marc , Asberger Jasmin , van Oostrum Jan , Casares de Cal María de los Ángeles , Gómez-Tato Antonio , Reventos Jaume , Domon Bruno , Colas Eva , Gil-Moreno Antonio
Published: April 2023

Supplementary Table S5. Clinico-pathological characteristics of the 38 women from a previous study used to validate the robustness of the diagnostic panel.
Supplementary Fig 13 from WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Authors: Luke Jason J. , Bao Riyue , Sweis Randy F. , Spranger Stefani , Gajewski Thomas F.
Published: April 2023

Sup Fig 13
Supplementary Fig 12 from WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Authors: Luke Jason J. , Bao Riyue , Sweis Randy F. , Spranger Stefani , Gajewski Thomas F.
Published: April 2023

Sup Fig 12
Supplementary Fig 1 from WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Authors: Luke Jason J. , Bao Riyue , Sweis Randy F. , Spranger Stefani , Gajewski Thomas F.
Published: April 2023

Sup Fig 1
Figure S1 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
Authors: Siemeister Gerhard , Mengel Anne , Fernández-Montalván Amaury E. , Bone Wilhelm , Schröder Jens , Zitzmann-Kolbe Sabine , Briem Hans , Prechtl Stefan , Holton Simon J. , Mönning Ursula , von Ahsen Oliver , Johanssen Sandra , Cleve Arwed , Pütter Vera , Hitchcock Marion , von Nussbaum Franz , Brands Michael , Ziegelbauer Karl , Mumberg Dominik
Published: April 2023

Identification of a novel Bub1 inhibitor
supp Tables from Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy
Authors: Karnes R. Jeffrey , Sharma Vidit , Choeurng Voleak , Ashab Hussam Al-Deen , Erho Nicholas , Alshalalfa Mohammed , Trock Bruce , Ross Ashley , Yousefi Kasra , Tsai Harrison , Zhao Shuang G. , Tosoian Jeffrey J. , Haddad Zaid , Takhar Mandeep , Chang S. Laura , Spratt Daniel E. , Abdollah Firas , Jenkins Robert B. , Klein Eric A. , Nguyen Paul L. , Dicker Adam P. , Den Robert B. , Davicioni Elai , Feng Felix Y. , Lotan Tamara L. , Schaeffer Edward M.
Published: April 2023

Table 1: Clinicopathological characteristics of training and validation cohorts Table 2: Univariable and multivariable Cox regression of the validation set studying the interaction between ADT treatment and ADT-RS Table S1: List of NEPC related genes used for model discovery Table S2: List of ADT-RS genes and their coefficients in both arms in the final model Table S3: Clinicopathological characteristics of the matched validation set comparing treated-ADT patients to no-ADT treated patients Table S4: Survival c-indices in discriminating metatastic risk for three genomic signatures (ADT-RS, Decipher, cell cycle genes) across the three validation datasets. ADT-RS scores were multiplied by a factor of -1 so that higher scores reflect a higher risk of metastasis for comparison with the two prognostic-only models. Table S5: Marginal ADT by genomic biomarker interaction effect
Supplementary Figure 3 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Authors: Shah Manish A. , Starodub Alexander , Sharma Sunil , Berlin Jordan , Patel Manish , Wainberg Zev A. , Chaves Jorge , Gordon Michael , Windsor Kevin , Brachmann Carrie Baker , Huang Xi , Vosganian Greg , Maltzman Julia D. , Smith Victoria , Silverman Jeffrey A. , Lenz Heinz-Josef , Bendell Johanna C.
Published: April 2023

Free (red) and total (blue) MMP9 for each patient in the monotherapy cohorts at Day 15 and Day 43 or End of Study (Days 40-57). Individual patients are separated by light gray dashed lines and dose groups by black dashed lines. The horizontal line depicts lower limit of quantitation (LLOQ).
Supplementary Methods from Integrated Analysis Reveals Tubal- and Ovarian-Originated Serous Ovarian Cancer and Predicts Differential Therapeutic Responses
Authors: Hao Dapeng , Li Jingjing , Jia Shanshan , Meng Yuan , Zhang Chao , Wang Li , Di Li-jun
Published: April 2023

Supplementary Methods
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6 from Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity
Authors: Meulendijks Didier , Jacob Wolfgang , Voest Emile E. , Mau-Sorensen Morten , Martinez-Garcia Maria , Taus Alvaro , Fleitas Tania , Cervantes Andres , Lolkema Martijn P. , Langenberg Marlies H.G. , De Jonge Maja J. , Sleijfer Stefan , Han Ji-Youn , Calles Antonio , Felip Enriqueta , Kim Sang-We , Schellens Jan H.M. , Wilson Sabine , Thomas Marlene , Ceppi Maurizio , Meneses-Lorente Georgina , James Ian , Vega-Harring Suzana , Dua Rajiv , Nguyen Maitram , Steiner Lori , Adessi Celine , Michielin Francesca , Bossenmaier Birgit , Weisser Martin , Lassen Ulrik N.
Published: April 2023

Supplementary Figure 1 Quantile plots of baseline membrane HER3 IRS score (A) and HER3 mRNA log expression (B) in baseline FFPE tumor biopsy samples from patients with known adeno- and squamous cell carcinoma histology Supplementary Figure 2 Quantile plots of baseline membrane HER3 immuno-reactive scores in fresh FFPE tumor biopsies from NSCLC patients with non-squamous or squamous histology Supplementary Figure 3 Quantile plots of baseline HRG mRNA log expression determined by qRT-PCR in FFPE tumor biopsies of adeno- and squamous cell carcinoma histology (data obtained using the HRG research assay) Supplementary Figure 4 Baseline HRG mRNA log expression in FFPE tumor biopsies, determined by qRT-PCR, in non-sqNSCLC and sqNSCLC (data obtained using the HRG prototype diagnostic assay). Dotted line indicates prior determined median HRG expression in sqNSCLC. Supplementary Figure 5 Best percentage change from baseline in sum of longest diameters of target lesions for patients in the dose escalation and extension phase of the cetuximab part (n = 38). Red bars indicate PD patients, blue bars SD patients, light green bars PR patients and dark green bars CR patients. Eleven patients were without target lesion assessment post baseline. Tumor type and lumretuzumab dose are indicated. * indicates patients who received previous EGFR-targeting therapy. a indicates a patient who received prior trastuzumab therapy. Supplementary Figure 6 Best percentage change from baseline in sum of longest diameters of target lesions for patients in the dose escalation phase and the two NRG1 fusion gene patients of the extension phase of the erlotinib part (n = 31). Red bars indicate PD patients, blue bars SD patients and green bars PR patients. Eight patients were without target lesion assessment post baseline. Tumor type and lumretuzumab dose are indicated. * indicates patients who received previous EGFR-targeting therapy. a indicates two patients with NRG1 gene fusion.
Figure S4 from Integrated Analysis Reveals Tubal- and Ovarian-Originated Serous Ovarian Cancer and Predicts Differential Therapeutic Responses
Authors: Hao Dapeng , Li Jingjing , Jia Shanshan , Meng Yuan , Zhang Chao , Wang Li , Di Li-jun
Published: April 2023

IHC staining of COL11A1, calretinin and PAX8 of ovarian cancer tissues
Supplementary Tables from Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations
Authors: Yao Yung-mae M. , Donoho Gregory P. , Iversen Philip W. , Zhang Youyan , Van Horn Robert D. , Forest Amelie , Novosiadly Ruslan D. , Webster Yue Wang , Ebert Philip , Bray Steven , Ting Jason C. , Aggarwal Amit , Henry James R. , Tiu Ramon V. , Plowman Gregory D. , Peng Sheng-Bin
Published: April 2023

Supplementary Table S1 and S2
Figure S2 from Integrated Analysis Reveals Tubal- and Ovarian-Originated Serous Ovarian Cancer and Predicts Differential Therapeutic Responses
Authors: Hao Dapeng , Li Jingjing , Jia Shanshan , Meng Yuan , Zhang Chao , Wang Li , Di Li-jun
Published: April 2023

NMF clustering of SOCs using DEGs between FT and OSE
Supplementary Materials from A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Authors: Mayer Ingrid A. , Prat Aleix , Egle Daniel , Blau Sibel , Fidalgo J. Alejandro Pérez , Gnant Michael , Fasching Peter A. , Colleoni Marco , Wolff Antonio C. , Winer Eric P. , Singer Christian F. , Hurvitz Sara , Estévez Laura García , van Dam Peter A. , Kümmel Sherko , Mundhenke Christoph , Holmes Frankie , Babbar Naveen , Charbonnier Laure , Diaz-Padilla Ivan , Vogl Florian D. , Sellami Dalila , Arteaga Carlos L.
Published: April 2023

Contains supplementary tables and methods
Table S1 from Cyclophilin A Maintains Glioma-Initiating Cell Stemness by Regulating Wnt/β-Catenin Signaling
Authors: Wang Guangzhi , Shen Jia , Sun Jiahang , Jiang Zhenfeng , Fan Jiabing , Wang Hongjun , Yu Shan , Long Yu , Liu Yi , Bao Hongbo , Zhang Kelvin Xi , Han Ke , Zhu Minwei , Zheng Yongri , Lin Zhiguo , Jiang Chuanlu , Guo Mian
Published: April 2023

Oligonucleotide sequences
Figure S5 from Cyclophilin A Maintains Glioma-Initiating Cell Stemness by Regulating Wnt/β-Catenin Signaling
Authors: Wang Guangzhi , Shen Jia , Sun Jiahang , Jiang Zhenfeng , Fan Jiabing , Wang Hongjun , Yu Shan , Long Yu , Liu Yi , Bao Hongbo , Zhang Kelvin Xi , Han Ke , Zhu Minwei , Zheng Yongri , Lin Zhiguo , Jiang Chuanlu , Guo Mian
Published: April 2023

CSA inhibits Wnt/β-catenin signaling activity and GICs self-renewal
Figure S4 from Cyclophilin A Maintains Glioma-Initiating Cell Stemness by Regulating Wnt/β-Catenin Signaling
Authors: Wang Guangzhi , Shen Jia , Sun Jiahang , Jiang Zhenfeng , Fan Jiabing , Wang Hongjun , Yu Shan , Long Yu , Liu Yi , Bao Hongbo , Zhang Kelvin Xi , Han Ke , Zhu Minwei , Zheng Yongri , Lin Zhiguo , Jiang Chuanlu , Guo Mian
Published: April 2023

CypA activates Wnt/β-catenin signaling
Supplementary table 1 from Burden and Profile of Somatic Mutation in Duodenal Adenomas from Patients with Familial Adenomatous- and MUTYH-associated Polyposis
Authors: Thomas Laura E. , Hurley Joanna J. , Meuser Elena , Jose Sian , Ashelford Kevin E. , Mort Matthew , Idziaszczyk Shelley , Maynard Julie , Brito Helena Leon , Harry Manon , Walters Angharad , Raja Meera , Walton Sarah-Jane , Dolwani Sunil , Williams Geraint T. , Morgan Meleri , Moorghen Morgan , Clark Susan K. , Sampson Julian R.
Published: April 2023

Pre- and Post-validation protein altering somatic variants identified by whole exome sequencing.
Supplementary_Figure_Legends from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo
Authors: Morrow James J. , Mendoza Arnulfo , Koyen Allyson , Lizardo Michael M. , Ren Ling , Waybright Timothy J. , Hansen Ryan J. , Gustafson Daniel L. , Zhou Ming , Fan Timothy M. , Scacheri Peter C. , Khanna Chand
Published: April 2023

Legends for Supplementary Tables and Figures
Supplementary Table 1 from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo
Authors: Morrow James J. , Mendoza Arnulfo , Koyen Allyson , Lizardo Michael M. , Ren Ling , Waybright Timothy J. , Hansen Ryan J. , Gustafson Daniel L. , Zhou Ming , Fan Timothy M. , Scacheri Peter C. , Khanna Chand
Published: April 2023

Summary of BONCAT proteomic analysis of mRNA translation during metastasis
Supplementary Tables from Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
Authors: Horikawa Naoki , Abiko Kaoru , Matsumura Noriomi , Hamanishi Junzo , Baba Tsukasa , Yamaguchi Ken , Yoshioka Yumiko , Koshiyama Masafumi , Konishi Ikuo
Published: April 2023

Supplementary tables
Supplementary Figure 2 from Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
Authors: Horikawa Naoki , Abiko Kaoru , Matsumura Noriomi , Hamanishi Junzo , Baba Tsukasa , Yamaguchi Ken , Yoshioka Yumiko , Koshiyama Masafumi , Konishi Ikuo
Published: April 2023

Survival analysis for clinical samples and phenotype analysis of patients' MDSCs
Supplemental Methods and Legends from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Authors: Doostan Iman , Karakas Cansu , Kohansal Mehrnoosh , Low Kwang-Hui , Ellis Matthew J. , Olson John A. , Suman Vera J. , Hunt Kelly K. , Moulder Stacy L. , Keyomarsi Khandan
Published: April 2023

The file contains supplemental methods pertaining to the supplemental figures and supplemental figure legends
Supplemental Figure S3. from The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression–Based Meta-Analysis
Authors: Stover Daniel G. , Coloff Jonathan L. , Barry William T. , Brugge Joan S. , Winer Eric P. , Selfors Laura M.
Published: April 2023

Association of Gene Expression Signatures with Response to Neoadjuvant Chemotherapy.
Supplementary Data from Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
Authors: Gauci Marie-Léa , Lanoy Emilie , Champiat Stéphane , Caramella Caroline , Ammari Samy , Aspeslagh Sandrine , Varga Andrea , Baldini Capucine , Bahleda Rastilav , Gazzah Anas , Michot Jean-Marie , Postel-Vinay Sophie , Angevin Eric , Ribrag Vincent , Hollebecque Antoine , Soria Jean-Charles , Robert Caroline , Massard Christophe , Marabelle Aurélien
Published: April 2023

Sup Data Table S1: Characteristic features of long responder patients Sup Data Figure S1: a: PFS and OS from the first objective response assessed for responder patients; b: PFS and OS from the first objective response assessed for partial responders; c: OS and PFS from the first complete response assessed (crPFS and crOS) Sup Data Figure S2: Risk of relapse upon therapy discontinuation function of therapy duration Sup Data Figure S3: Survival from relapse and PFS from OR of secondary refractory disease Sup Data Figure S4: PFS from OR of secondary refractory disease function of tumor type Sup Data Table S2: Characteristics of secondary refractory disease Sup Data Table S3: Characteristics of long survival after immunotherapy initiation with progression first response/stable disease then progression: n=30 (%) Sup Data Table S4: Objective response rate (ORR) as a function of tumor type (%) Sup Data Figure S5a: PFS function of RMH score Sup Data Figure S5b: OS function of the RMH score Sup Data Figure 6: a: Overall survival function of NLR, b: Overall survival for patients presenting progressive disease as best response function of the NLR, c: Overall survival for patients presenting stable disease as best response function of the NLR d: Overall survival for patients presenting objective response as best response function of the NLR Sup Data Figure S7: a: Response function of neutrophil and lymphocyte counts, b: comparison of lymphocyte count function of response, c: comparison of neutrophil count function of response
Supplementary Figure S1 from Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer
Authors: Duran Rafael , Mirpour Sahar , Pekurovsky Vasily , Ganapathy-Kanniappan Shanmugasundaram , Brayton Cory F. , Cornish Toby C. , Gorodetski Boris , Reyes Juvenal , Chapiro Julius , Schernthaner Rüdiger E. , Frangakis Constantine , Lin MingDe , Sun Jessica D. , Hart Charles P. , Geschwind Jean-François
Published: April 2023

Supplementary Figure S1: Quantitative volumetric image analysis.
Supplementary Table 2 from Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study
Authors: Pinto Emilia Modolo , Rodriguez-Galindo Carlos , Choi John Kim , Pounds Stanley , Liu Zhifa , Neale Geoffrey , Finkelstein David , Hicks John M. , Pappo Alberto S. , Figueiredo Bonald C. , Ribeiro Raul C. , Zambetti Gerard P.
Published: April 2023

Identification of 38 Probe-sets for Expression Analysis of MHC Class II and Selected CD Marker Genes
Supplementary methods, results from Identification of a Novel ITGαvβ6-Binding Peptide Using Protein Separation and Phage Display
Authors: Altmann Annette , Sauter Max , Roesch Saskia , Mier Walter , Warta Rolf , Debus Jürgen , Dyckhoff Gerhard , Herold-Mende Christel , Haberkorn Uwe
Published: April 2023

Description of methods, results, legends of supplementary figures
Supplementary Figures S1-4 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
Authors: Ma Cynthia X. , Gao Feng , Luo Jingqin , Northfelt Donald W. , Goetz Matthew , Forero Andres , Hoog Jeremy , Naughton Michael , Ademuyiwa Foluso , Suresh Rama , Anderson Karen S. , Margenthaler Julie , Aft Rebecca , Hobday Timothy , Moynihan Timothy , Gillanders William , Cyr Amy , Eberlein Timothy J. , Hieken Tina , Krontiras Helen , Guo Zhanfang , Lee Michelle V. , Spies Nicholas C. , Skidmore Zachary L. , Griffith Obi L. , Griffith Malachi , Thomas Shana , Bumb Caroline , Vij Kiran , Bartlett Cynthia Huang , Koehler Maria , Al-Kateb Hussam , Sanati Souzan , Ellis Matthew J.
Published: April 2023

Supplementary Fig. S1 is the consort diagram; Supplementary Fig. S2 describes the clinicopathologic and molecular features of the 6 palbociclib resistant tumors; Supplementary Fig S3 shows the proliferation score and correlation with Ki67 at each time point; Supplementary Fig S4 shows the heatmap of the proliferation score genes and ER regulated genes
Supplemental Table 2 from Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
Authors: Offin Michael , Rizvi Hira , Tenet Megan , Ni Andy , Sanchez-Vega Francisco , Li Bob T. , Drilon Alexander , Kris Mark G. , Rudin Charles M. , Schultz Nikolaus , Arcila Maria E. , Ladanyi Marc , Riely Gregory J. , Yu Helena , Hellmann Matthew D.
Published: April 2023

Demographics by EGFR-mutant allele and smoking status
Supplemental Table 1 from Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
Authors: Offin Michael , Rizvi Hira , Tenet Megan , Ni Andy , Sanchez-Vega Francisco , Li Bob T. , Drilon Alexander , Kris Mark G. , Rudin Charles M. , Schultz Nikolaus , Arcila Maria E. , Ladanyi Marc , Riely Gregory J. , Yu Helena , Hellmann Matthew D.
Published: April 2023

Full annotated cohort of EGFR-mutant lung cancer patients evaluated (n = 153)
Table S3 from A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors
Authors: Evans Kurt W. , Yuca Erkan , Akcakanat Argun , Scott Stephen M. , Arango Natalia Paez , Zheng Xiaofeng , Chen Ken , Tapia Coya , Tarco Emily , Eterovic Agda K. , Black Dalliah M. , Litton Jennifer K. , Yap Timothy A. , Tripathy Debu , Mills Gordon B. , Meric-Bernstam Funda
Published: April 2023

Correlations to TNBCtypes
Supplementary File 1 from A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
Authors: Paik Paul K. , Shen Ronglai , Berger Michael F. , Ferry David , Soria Jean-Charles , Mathewson Alastair , Rooney Claire , Smith Neil R. , Cullberg Marie , Kilgour Elaine , Landers Donal , Frewer Paul , Brooks Nigel , André Fabrice
Published: April 2023

MSK-IMPACT gene list
Supplementary Methods from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Authors: Moreno Laura , Perez Cristina , Zabaleta Aintzane , Manrique Irene , Alignani Diego , Ajona Daniel , Blanco Laura , Lasa Marta , Maiso Patricia , Rodriguez Idoia , Garate Sonia , Jelinek Tomas , Segura Victor , Moreno Cristina , Merino Juana , Rodriguez-Otero Paula , Panizo Carlos , Prosper Felipe , San-Miguel Jesus F. , Paiva Bruno
Published: April 2023

Supplementary Methods
Figure S3B from Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
Authors: Edwards Jarem , Tasker Annie , Pires da Silva Inês , Quek Camelia , Batten Marcel , Ferguson Angela , Allen Ruth , Allanson Benjamin , Saw Robyn P.M. , Thompson John F. , Menzies Alexander M. , Palendira Umaimainthan , Wilmott James S. , Long Georgina V. , Scolyer Richard A.
Published: April 2023

VISTA expression on immune cells in tumor dissociates by flow cytometry
Supplemental Figures from Machine Learning–Based Radiomics for Molecular Subtyping of Gliomas
Authors: Lu Chia-Feng , Hsu Fei-Ting , Hsieh Kevin Li-Chun , Kao Yu-Chieh Jill , Cheng Sho-Jen , Hsu Justin Bo-Kai , Tsai Ping-Huei , Chen Ray-Jade , Huang Chao-Ching , Yen Yun , Chen Cheng-Yu
Published: April 2023

Figure S1. Inclusion Flowchart. Figure S2. Diagram of the image processing. Figure S3. Profiles of the Radiomic Features.
Supplementary Fig S1-S5 from Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer
Authors: Li Shuai , Liu Shengwu , Deng Jiehui , Akbay Esra A. , Hai Josephine , Ambrogio Chiara , Zhang Long , Zhou Fangyu , Jenkins Russell W. , Adeegbe Dennis O. , Gao Peng , Wang Xiaoen , Paweletz Cloud P. , Herter-Sprie Grit S. , Chen Ting , Gutiérrez-Quiceno Laura , Zhang Yanxi , Merlino Ashley A. , Quinn Max M. , Zeng Yu , Yu Xiaoting , Liu Yuting , Fan Lichao , Aguirre Andrew J. , Barbie David A. , Yi Xianghua , Wong Kwok-Kin
Published: April 2023

Supplementary Figures 1-5
Figure S4 from MELK Inhibition in Diffuse Intrinsic Pontine Glioma
Authors: Meel Michaël H. , de Gooijer Mark C. , Guillén Navarro Miriam , Waranecki Piotr , Breur Marjolein , Buil Levi C.M. , Wedekind Laurine E. , Twisk Jos W.R. , Koster Jan , Hashizume Rintaro , Raabe Eric H. , Montero Carcaboso Angel , Bugiani Marianna , van Tellingen Olaf , van Vuurden Dannis G. , Kaspers Gertjan J.L. , Hulleman Esther
Published: April 2023

Western blot showing MELK expression in VUMC-DIPG-F cells compared to JHH-DIPG-01 cells.
Supplementary Table S1 from Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer
Authors: Vantaku Venkatrao , Dong Jianrong , Ambati Chandrashekar R. , Perera Dimuthu , Donepudi Sri Ramya , Amara Chandra Sekhar , Putluri Vasanta , Ravi Shiva Shankar , Robertson Matthew J. , Piyarathna Danthasinghe Waduge Badrajee , Villanueva Mariana , von Rundstedt Friedrich-Carl , Karanam Balasubramanyam , Ballester Leomar Y. , Terris Martha K. , Bollag Roni J. , Lerner Seth P. , Apolo Andrea B. , Villanueva Hugo , Lee MinJae , Sikora Andrew G. , Lotan Yair , Sreekumar Arun , Coarfa Cristian , Putluri Nagireddy
Published: April 2023

Supplementary Table S1. List of internal standards for metabololomics and lipidomics, spiked across the various profiling platforms.
Supplementary Appendix from Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders
Authors: Grisham Rachel N. , Moore Kathleen N. , Gordon Michael S. , Harb Wael , Cody Gwendolyn , Halpenny Darragh F. , Makker Vicky , Aghajanian Carol A.
Published: April 2023

Table S1. Plasma pharmacokinetic sampling times Table S2. Identified Alterations, Listed by Patient Table S3. Adverse events reported in {greater than or equal to}10% of patients (safety cohort) Table S4. Grade 3 to 5 adverse events reported in >1 patient (safety cohort) Table S5. Evaluation of Best Overall Response in Patients with Initial Measurable Disease and Evaluable by CA-125 Figure S1. Geometric mean (standard deviation) plasma concentrations of binimetinib (top) and its metabolite AR00426032 (bottom) on cycle 1 days 7, 8, and 15: semi-logarithmic scale (pharmacokinetic set [30 mg BID binimetinib continuous]) Figure S2. Geometric mean (standard deviation) plasma concentrations of binimetinib (top) and its metabolite AR00426032 (bottom) on cycle 1 days 7, 8, and 15: semi-logarithmic scale (pharmacokinetic set [45 mg BID binimetinib continuous]) Figure S3. Geometric mean (standard deviation) plasma concentrations of binimetinib (top) and its metabolite AR00426032 (bottom) on cycle 1 days 1, 8, and 15: semi-logarithmic scale (pharmacokinetic set [45 mg BID binimetinib intermittent]) Figure S4. Representative CT Resolution of Implant in a Complete Responder
Supplementary Figure S6 from Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer
Authors: Vantaku Venkatrao , Dong Jianrong , Ambati Chandrashekar R. , Perera Dimuthu , Donepudi Sri Ramya , Amara Chandra Sekhar , Putluri Vasanta , Ravi Shiva Shankar , Robertson Matthew J. , Piyarathna Danthasinghe Waduge Badrajee , Villanueva Mariana , von Rundstedt Friedrich-Carl , Karanam Balasubramanyam , Ballester Leomar Y. , Terris Martha K. , Bollag Roni J. , Lerner Seth P. , Apolo Andrea B. , Villanueva Hugo , Lee MinJae , Sikora Andrew G. , Lotan Yair , Sreekumar Arun , Coarfa Cristian , Putluri Nagireddy
Published: April 2023

Supplementary Figure S6. Survival analysis of individual downregulated genes showed poor prognosis associated with CPT1B and PIGB in the Lindgren and Sjodahl cohorts; PLA2G4A in the Lindgren cohort; PIGV in the Kim and Sjodahl cohorts; ATP8B1 in the Kim and Sjodahl cohorts; INPP5D in the Kim and Sjodahl cohorts; PIGZ in the Kim and Sjodahl cohorts; PLCD3 in the Sjodahl cohort; and PLA2G10 in the Kim cohort.
Figure S4 from Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Authors: Jiang Yuming , Xie Jingjing , Han Zhen , Liu Wei , Xi Sujuan , Huang Lei , Huang Weicai , Lin Tian , Zhao Liying , Hu Yanfeng , Yu Jiang , Zhang Qi , Li Tuanjie , Cai Shirong , Li Guoxin
Published: April 2023

Figure S4. Kaplan-Meier survival analysis of OS for patients in the internal validation cohort according to the GC-SVM classifier stratified by clinicopathological risk factors. P-values were calculated by log-rank test.
Table S4 from Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Authors: Atkins Michael B. , Hodi F. Stephen , Thompson John A. , McDermott David F. , Hwu Wen-Jen , Lawrence Donald P. , Dawson Nancy A. , Wong Deborah J. , Bhatia Shailender , James Marihella , Jain Lokesh , Robey Seth , Shu Xinxin , Homet Moreno Blanca , Perini Rodolfo F. , Choueiri Toni K. , Ribas Antoni
Published: April 2023

Treatment-Related Adverse Events Occurring in {greater than or equal to}1 Patient Treated With Pembrolizumab plus Pegylated Interferon alfa-2b
Supplementary Figure 5 from CKLF1 Enhances Inflammation-Mediated Carcinogenesis and Prevents Doxorubicin-Induced Apoptosis via IL6/STAT3 Signaling in HCC
Authors: Liu Youyi , Liu Lijuan , Zhou Yan , Zhou Ping , Yan Qiujin , Chen Xiaobei , Ding Shuang , Zhu Fan
Published: April 2023

CKLF1 regulates the activation of IL-6/STAT3 signaling pathway.
Table S4 from Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer
Authors: Bonazzoli Elena , Predolini Federica , Cocco Emiliano , Bellone Stefania , Altwerger Gary , Menderes Gulden , Zammataro Luca , Bianchi Anna , Pettinella Francesca , Riccio Francesco , Han Chanhee , Yadav Ghanshyam , Lopez Salvatore , Manzano Aranzazu , Manara Paola , Buza Natalia , Hui Pei , Wong Serena , Litkouhi Babak , Ratner Elena , Silasi Dan-Arin , Huang Gloria S. , Azodi Masoud , Schwartz Peter E. , Schlessinger Joseph , Santin Alessandro D.
Published: April 2023

Average quantitative nuclear histological score associated with the ex vivo c-Myc expression assessed by IHC in the ARK2 xenograft tumor samples, excised 1 hour and 6 hours after a single dose of GS-5829 at 40, 20, 10 mg/kg, GS-626510 at 10 mg/kg and vehicle for oral gavage studies.
Supplementary Figure S1: Study selection from Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer
Authors: Wouters Maartje C.A. , Nelson Brad H.
Published: April 2023

Study selection
Table S7-12 from The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
Authors: Zill Oliver A. , Banks Kimberly C. , Fairclough Stephen R. , Mortimer Stefanie A. , Vowles James V. , Mokhtari Reza , Gandara David R. , Mack Philip C. , Odegaard Justin I. , Nagy Rebecca J. , Baca Arthur M. , Eltoukhy Helmy , Chudova Darya I. , Lanman Richard B. , Talasaz AmirAli
Published: April 2023

Mutual exclusivity statistics for cfDNA alterations in lung adenocarcinoma, breast cancer, and colorectal cancer
Table S6 from The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
Authors: Zill Oliver A. , Banks Kimberly C. , Fairclough Stephen R. , Mortimer Stefanie A. , Vowles James V. , Mokhtari Reza , Gandara David R. , Mack Philip C. , Odegaard Justin I. , Nagy Rebecca J. , Baca Arthur M. , Eltoukhy Helmy , Chudova Darya I. , Lanman Richard B. , Talasaz AmirAli
Published: April 2023

Driver alteration prevalence in the cfDNA cohort versus in TCGA
Supplemental Materials from The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
Authors: Zill Oliver A. , Banks Kimberly C. , Fairclough Stephen R. , Mortimer Stefanie A. , Vowles James V. , Mokhtari Reza , Gandara David R. , Mack Philip C. , Odegaard Justin I. , Nagy Rebecca J. , Baca Arthur M. , Eltoukhy Helmy , Chudova Darya I. , Lanman Richard B. , Talasaz AmirAli
Published: April 2023

Supplemental Methods, Supplemental References, Supplemental Figure Legends, Figure S1-13, Table S1-5 and S14
Table S2 from Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts
Authors: Kim Kwanghee , Watson Philip A. , Lebdai Souhil , Jebiwott Sylvia , Somma Alexander J. , La Rosa Stephen , Mehta Dipti , Murray Katie S. , Lilja Hans , Ulmert David , Monette Sebastien , Scherz Avigdor , Coleman Jonathan A.
Published: April 2023

C2_CP gene set
Supplementary Data from Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer
Authors: Brooks Jill M. , Menezes Albert N. , Ibrahim Maha , Archer Lucinda , Lal Neeraj , Bagnall Christopher J. , von Zeidler Sandra V. , Valentine Helen R. , Spruce Rachel J. , Batis Nikolaos , Bryant Jennifer L. , Hartley Margaret , Kaul Baksho , Ryan Gordon B. , Bao Riyue , Khattri Arun , Lee Steven P. , Ogbureke Kalu U.E. , Middleton Gary , Tennant Daniel A. , Beggs Andrew D. , Deeks Jonathan , West Catharine M. L. , Cazier Jean-Baptiste , Willcox Benjamin E. , Seiwert Tanguy Y. , Mehanna Hisham
Published: April 2023

Figure S1. Gene order within the cluster defined groups. Figure S2. Analysis of individual hypoxia and immune gene signatures. Figure S3. Flow diagram showing progress of patient samples through study for Correlate cohort Figure S4. Relationship between heatmap defined hypoxia-immune subgroups and T stage. Figure S5 Expression of individual hypoxia- or immune-response related genes within the heat-map defined subgroups. Figure S6. Correlation of PD-L1 or CA-IX protein expression with survival. Figure S7 Correlation of gene and protein expression. Figure S8. Spatial interactions of hypoxia and immune cells: Vectra images of multiplex stained HNC sections. Table S1 Treatment schedules Table S2. Genes in the RNASeq panel/TCGA dataset Table S3. Relationship of hypoxia-immune classifier to other prognostic variables Table S4. Summary of immunohistochemistry staining Table S5. Summary of statistical analyses for IHC staining